NDA Accepted for Saflutan for Glaucoma - ONA
Links shared publicly online about this topic.
- 451total visits
NDA Accepted for Saflutan for Glaucoma - ONA
View full resource at oncologynurseadvisor.com
Tags: Heart Disease, High Blood Pressure, Glaucoma, Drug, FDA, Merck & Co.
Most Recently Shared on March 9, 2011 at 6:23 pm By:
NDA Accepted for Saflutan for Glaucoma http://goo.gl/fb/aCszL
Merck Announces FDA Acceptance Of New Drug Application For Investigational Ophthalmic Medication SAFLUTAN(R) (Tafluprost)
medicalnewstoday.com — “Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the New Drug Application (NDA) for SAFLUTAN® (tafluprost), Merck's investigational preservative-free p” View full resource at medicalnewstoday.com
Most Recently Shared on March 13, 2011 at 8:05 am By:
Merck Announces FDA Acceptance Of New Drug Application For Investigational Ophthalmic Medication SAFLUTAN(R) (Tafluprost) http://mnt.to/3SbT
FDA accepts Merck's SAFLUTAN NDA for standard review
news-medical.net — “Merck, known as MSD outside the United States and Canada, announced today that the New Drug Application for SAFLUTAN, Merck's investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S. Food and Drug Administration.” View full resource at news-medical.net
Most Recently Shared on March 10, 2011 at 5:06 am By:
FDA accepts Merck's SAFLUTAN NDA for standard review: Merck, known as MSD outside the United States and Canada, ... http://bit.ly/g9Ozy6
NDA Accepted for Saflutan for Glaucoma - MPR
empr.com — “Merck announced that the FDA has accepted its New Drug Application for Saflutan (tafluprost ophthalmic solution) for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.” View full resource at empr.com
Most Recently Shared on March 9, 2011 at 6:53 pm By:
MPR News: NDA Accepted for Saflutan for Glaucoma: Merck announced that the FDA has accepted its New Drug Applica... http://bit.ly/dFl7IR
Advertisement
